Last $11.85 USD
Change Today -0.44 / -3.58%
Volume 235.1K
OMER On Other Exchanges
Symbol
Exchange
Berlin
As of 8:10 PM 04/23/14 All times are local (Market data is delayed by at least 15 minutes).

omeros corp (OMER) Snapshot

Open
$12.25
Previous Close
$12.29
Day High
$12.27
Day Low
$11.80
52 Week High
02/28/14 - $14.69
52 Week Low
05/2/13 - $3.77
Market Cap
395.8M
Average Volume 10 Days
366.8K
EPS TTM
$-1.67
Shares Outstanding
33.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for OMEROS CORP (OMER)

omeros corp (OMER) Related Bloomberg News

View More Bloomberg News

omeros corp (OMER) Related Businessweek News

No Related Businessweek News Found

omeros corp (OMER) Details

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes products targeting inflammation, coagulopathies, and disorders of the central nervous system. Its clinical products include Omidria, which has completed two Phase III clinical trials for use during intraocular lens replacement, including cataract and other lens replacement surgery; OMS103 that is in Phase III clinical program for use during arthroscopic procedures, such as partial meniscectomy surgery; and OMS824, which is in Phase II clinical trial for the treatment of CNS disorders comprising schizophrenia and Huntington's disease. Its clinical programs also consist of OMS721 that is in Phase II clinical trial for the treatment of various complement-related diseases and disorders, including thrombotic microangiopathies; OMS405, which is in Phase II clinical trial for the treatment and prevention of addiction to substances of abuse; and OMS201 that has completed Phase 1/Phase 2 clinical trial for use during urological procedures, such as ureterscopy for removal of ureteral or renal stones. The company’s preclinical products and development programs comprise OMS527 for the treatment of addiction and compulsive disorders, as well as for movement disorders, such as Parkinson's disease; and OMS616 for the control of blood loss during surgery, or resulting from trauma or other hyperfibrinolytic conditions. Its preclinical products also include G protein-coupled receptors platform for multiple disorders across therapeutic area; GPR17 for demyelinating disorders; and antibody platform for the discovery of monoclonal antibodies. Omeros Corporation was incorporated in 1994 and is based in Seattle, Washington.

75 Employees
Last Reported Date: 03/13/14
Founded in 1994

omeros corp (OMER) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $763.7K
Vice President of Patent, General Counsel and...
Total Annual Compensation: $393.9K
Compensation as of Fiscal Year 2012.

omeros corp (OMER) Key Developments

Omeros Corporation announces Investigational New Drug Application Cleared by FDA for OMS721 in Thrombotic Microangiopathies

Omeros Corporation announced that its Investigational New Drug Application (IND) to evaluate OMS721 for the inhibition of complement--mediated thrombotic microangiopathies (TMAs) has been cleared by the U.S. Food and Drug Administration (FDA). OMS721 is the company's human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the key regulator of the lectin pathway of the immune system. FDA's clearance of the IND allows the initiation of the Phase 2 program for OMS721, which will assess the efficacy and safety of OMS721 in patients with disorders associated with lectin pathway activation. The first OMS721 Phase 2 clinical trial, planned to begin later this quarter, will evaluate the effects of the drug on patients with TMAs, including atypical hemolytic uremic syndrome (aHUS), thrombotic thrombocytopenic purpura (TTP), and stem cell transplant-related TMA. The lectin pathway, one of the principal complement activation pathways in the immune system, is thought to play a central role in the development of TMAs, and OMS721, by targeting and inhibiting MASP-2, blocks the lectin pathway. Omeros controls the worldwide rights to MASP-2 inhibition and to all therapeutics targeting MASP-2, a novel pro-inflammatory protein target involved in activation of the complement system, which is an important component of the immune system. The complement system plays a role in the inflammatory response and becomes activated as a result of tissue damage or microbial infection. MASP-2 appears to be unique to, and required for the function of, one of the principal complement activation pathways, known as the lectin pathway. Importantly, inhibition of MASP-2 does not appear to interfere with the antibody-dependent classical complement activation pathway, which is a critical component of the acquired immune response to infection, and its abnormal function is associated with a wide range of autoimmune disorders. MASP-2 is generated by the liver and is then released into the circulation.

Omeros Corporation Presents at 13th Annual Needham Healthcare Conference, Apr-09-2014 03:00 PM

Omeros Corporation Presents at 13th Annual Needham Healthcare Conference, Apr-09-2014 03:00 PM. Venue: The Westin Grand Central Hotel, New York, New York, United States. Speakers: Gregory A. Demopulos, Co-Founder, Chairman, Chief Executive Officer and President.

Omeros Corporation Auditor Raises 'Going Concern' Doubt

Omeros Corporation filed its 10-K on Mar 13, 2014 for the period ending Dec 31, 2013. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OMER:US $11.85 USD -0.44

OMER Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OMER.
View Industry Companies
 

Industry Analysis

OMER

Industry Average

Valuation OMER Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 232.7x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 238.5x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OMEROS CORP, please visit www.omeros.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.